Although our data showed a clear trend toward longitudinal improvement in lung function over time in the treatment group, the results should be interpreted with caution, as only patients with medication records and pulmonary function test reports within 6-month follow-up were included, which may overestimate the drug effectiveness to some extent.
← all excerpts
Real-world therapeutic performance of pirfenidone for connective tissue disease-associated interstitial lung diseases.
1
—
—